BRKR
Undervalued by 79.7% based on the discounted cash flow analysis.
Market cap | $5.61 Billion |
---|---|
Enterprise Value | $8.43 Billion |
Dividend Yield | $0.20 (0.54%) |
Earnings per Share | $0.76 |
Beta | 1.2 |
Outstanding Shares | 151,600,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 70.43 |
---|---|
PEG | - |
Price to Sales | 1.68 |
Price to Book Ratio | 3.08 |
Enterprise Value to Revenue | 2.45 |
Enterprise Value to EBIT | 97.37 |
Enterprise Value to Net Income | 105 |
Total Debt to Enterprise | 0.35 |
Debt to Equity | 1.6 |
No data
No data
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scienti c instruments and high-value analytical and diagnostic solutions enable...